Figure 4 | Scientific Reports

Figure 4

From: A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes

Figure 4

Schematic overview of three commercially available anti-VEGF biologics. Ranibizumab (a) is composed of the affinity maturated Fab of bevacizumab, (b) bevacizumab is a full-length IgG1 antibody and (c) aflibercept is composed of domains from VEGFR1 and 2 fused to an IgG1 Fc-region. The figure was created with BioRender software.

Back to article page